

ACADIA PHARMACEUTICALS INC  
Form 8-K  
August 10, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): August 10, 2005**

---

**ACADIA PHARMACEUTICALS INC.**

(Exact Name of Registrant as Specified in Charter)

---

**DELAWARE**  
(State or Other Jurisdiction  
of Incorporation)

**000-50768**  
(Commission File Number)

**06-1376651**  
(I.R.S. Employer  
Identification No.)

**3911 SORRENTO VALLEY BOULEVARD**

**SAN DIEGO, CALIFORNIA**  
(Address of Principal Executive Offices)

**92121**  
(Zip Code)

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 8-K

(858) 558-2871

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition**

On August 10, 2005, ACADIA Pharmaceuticals Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2005. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and herein has been furnished under Item 12 of this Report and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to liability under that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

**Item 9.01. Financial Statements and Exhibits**

(c) The following exhibit is furnished herewith:

99.1 Press release dated August 10, 2005

2.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

By: /s/ Thomas H. Aasen

Date: August 10, 2005

---

Thomas H. Aasen  
Vice President, Chief Financial Officer, Treasurer, and Secretary

3.

**INDEX TO EXHIBITS**

**Exhibit**

<u>Number</u>	<u>Description</u>
99.1	Press release dated August 10, 2005

4.